Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO

[1]  D. Moher,et al.  Listening to the Patient Voice Adds Value to Cancer Clinical Trials , 2022, Journal of the National Cancer Institute.

[2]  K. Weinfurt,et al.  Patient-Reported Outcome Measures in Clinical Research. , 2022, JAMA.

[3]  A. Bottomley,et al.  The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials , 2022, Clinical trials.

[4]  A. Regnault,et al.  Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease , 2021, Orphanet Journal of Rare Diseases.

[5]  M. King,et al.  Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: a systematic review of qualitative studies , 2021, Quality of Life Research.

[6]  M. Aadahl,et al.  Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis , 2021, Neuromuscular Disorders.

[7]  H. Andersen,et al.  Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis , 2020, Frontiers in Neurology.

[8]  I. Litchfield,et al.  Implementing PROMs in routine clinical care: a qualitative exploration of GP perspectives , 2020, BJGP open.

[9]  J. Verschuuren,et al.  Fatigue in patients with myasthenia gravis. A systematic review of the literature , 2020, Neuromuscular Disorders.

[10]  G. Cutter,et al.  Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study , 2020, Muscle & nerve.

[11]  P. Valko,et al.  Fatigue in patients with myasthenia gravis , 2018, Journal of Neurology.

[12]  R. Barohn,et al.  Measuring Clinical Treatment Response in Myasthenia Gravis. , 2018, Neurologic clinics.

[13]  S. Cano,et al.  Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures , 2017, Orphanet Journal of Rare Diseases.

[14]  J. Kissel,et al.  QMG and MG‐ADL correlations: Study of eculizumab treatment of myasthenia gravis , 2017, Muscle & nerve.

[15]  A. Davis,et al.  Development and validation of the Myasthenia Gravis Impairment Index , 2016, Neurology.

[16]  V. Bril,et al.  Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale , 2015, Journal of neuromuscular diseases.

[17]  S. Muppidi.  The Myasthenia Gravis‐Specific Activities of Daily Living Profile , 2012, Annals of the New York Academy of Sciences.

[18]  T. Burns.  The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice , 2012, Annals of the New York Academy of Sciences.

[19]  M. Benatar,et al.  Recommendations for myasthenia gravis clinical trials , 2012, Muscle & nerve.

[20]  M. Conaway,et al.  Psychometric evaluation of the myasthenia gravis composite using rasch analysis , 2012, Muscle & nerve.

[21]  V. Bril,et al.  The Quantitative Myasthenia Gravis Score: Comparison With Clinical, Electrophysiological, and Laboratory Markers , 2012, Journal of clinical neuromuscular disease.

[22]  N. Leidy,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  Elizabeth Molsen,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  M. Conaway,et al.  MG‐ADL: Still a relevant outcome measure , 2011, Muscle & nerve.

[25]  R. Leigh,et al.  Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles , 2011, Annals of the New York Academy of Sciences.

[26]  J. Hobart,et al.  Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. , 2009, Health technology assessment.

[27]  M. Conaway,et al.  Construction of an efficient evaluative instrument for Myasthenia Gravis: The MG composite , 2008, Muscle & nerve.

[28]  B. Gong,et al.  Extraocular Muscle Susceptibility to Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.

[29]  R. Barohn,et al.  Reliability Testing of the Quantitative Myasthenia Gravis Score a , 1998, Annals of the New York Academy of Sciences.

[30]  Georg Rasch,et al.  Probabilistic Models for Some Intelligence and Attainment Tests , 1981, The SAGE Encyclopedia of Research Design.

[31]  D. Andrich.  A rating formulation for ordered response categories , 1978 .

[32]  Graeme Hutcheson,et al.  Rasch Models for Measurement , 2011 .

[33]  D. Andrich.  Rating Scale Analysis , 1999 .